https://www.selleckchem.com/products/ipa-3.html
Based on the above findings, further structural modification will be conducted for the development of more potent kinase inhibitors as anticancer agents.Raloxifene agonism of estrogen receptor (ER) in post-menopausal endometrium is not negligible. Based on a rational drug design workflow, we synthesized 14 analogues of raloxifene bearing a polar group in the aromatic ring of the basic side chain (BSC) and/or changes in the bulkiness of the BSC amino group. Analogues with a polar BSC aromatic ring and amino group substituents of increasing